Effects of BMY-21502 on Anoxia in Mice

Manabu Amano, Takaaki Hasegawa, Toshitaka Nabeshima, Manabu Amano, Arata Goto, Norimitsu Takahash

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The protective effects of BMY-21502 (l-[[l-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone) against cerebral anoxia were investigated using various models in mice, in comparison with those of other cerebroactive drugs. Oral administration of BMY-21502 (10-100 mg/kg) significantly prolonged the survival time in KCN (2.4 mg/kg, i.v.)-induced anoxia. Oxiracetam and idebenone exerted similar but weak protection at doses above 100 mg/kg, p.o. and only at a dose of 1(X) mg/kg, P.O., respectively. Significant protection by BMY-21502 against moderate hypobaric hypoxia was observed at doses of 30 and 100 mg/kg, p.o. Idebenone (100 and 300 mg/kg, p.o.) significantly prolonged the survival time of mice in this model, but oxiracetam (30-300 mg/kg, p.o.) did not. Oral administration of all of these drugs (BMY-21502, 3-300 mg/kg; Oxiracetam, 100-1000 mg/kg; Idebenone, 100-1000 mg/kg) failed to increase the number of gasps and the duration of gasping in the decapitated head of mice as a complete ischemic model. The anti-anoxic effect of BMY-21502 in the KCN-anoxia model was blocked by pretreatment with scopolamine. These findings suggest that BMY-21502 has an anti-anoxic action superior to those of the other cerebroactive drugs used, and activation of the CNS cholinergic system is involved as one of the causative mechanisms for the anti-anoxic effect of BMY-21502.

Original languageEnglish
Pages (from-to)157-163
Number of pages7
JournalThe Japanese Journal of Pharmacology
Volume61
Issue number3
DOIs
Publication statusPublished - 01-01-1993
Externally publishedYes

Fingerprint

Oral Administration
Brain Hypoxia
Scopolamine Hydrobromide
BMY 21502
Hypoxia
Cholinergic Agents
Head
Pharmaceutical Preparations
idebenone
oxiracetam
2-pyrrolidone
Metabolic Activation

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Amano, M., Hasegawa, T., Nabeshima, T., Amano, M., Goto, A., & Takahash, N. (1993). Effects of BMY-21502 on Anoxia in Mice. The Japanese Journal of Pharmacology, 61(3), 157-163. https://doi.org/10.1254/jjp.61.157
Amano, Manabu ; Hasegawa, Takaaki ; Nabeshima, Toshitaka ; Amano, Manabu ; Goto, Arata ; Takahash, Norimitsu. / Effects of BMY-21502 on Anoxia in Mice. In: The Japanese Journal of Pharmacology. 1993 ; Vol. 61, No. 3. pp. 157-163.
@article{fb1af1f359694b69a5ede603eed05a86,
title = "Effects of BMY-21502 on Anoxia in Mice",
abstract = "The protective effects of BMY-21502 (l-[[l-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone) against cerebral anoxia were investigated using various models in mice, in comparison with those of other cerebroactive drugs. Oral administration of BMY-21502 (10-100 mg/kg) significantly prolonged the survival time in KCN (2.4 mg/kg, i.v.)-induced anoxia. Oxiracetam and idebenone exerted similar but weak protection at doses above 100 mg/kg, p.o. and only at a dose of 1(X) mg/kg, P.O., respectively. Significant protection by BMY-21502 against moderate hypobaric hypoxia was observed at doses of 30 and 100 mg/kg, p.o. Idebenone (100 and 300 mg/kg, p.o.) significantly prolonged the survival time of mice in this model, but oxiracetam (30-300 mg/kg, p.o.) did not. Oral administration of all of these drugs (BMY-21502, 3-300 mg/kg; Oxiracetam, 100-1000 mg/kg; Idebenone, 100-1000 mg/kg) failed to increase the number of gasps and the duration of gasping in the decapitated head of mice as a complete ischemic model. The anti-anoxic effect of BMY-21502 in the KCN-anoxia model was blocked by pretreatment with scopolamine. These findings suggest that BMY-21502 has an anti-anoxic action superior to those of the other cerebroactive drugs used, and activation of the CNS cholinergic system is involved as one of the causative mechanisms for the anti-anoxic effect of BMY-21502.",
author = "Manabu Amano and Takaaki Hasegawa and Toshitaka Nabeshima and Manabu Amano and Arata Goto and Norimitsu Takahash",
year = "1993",
month = "1",
day = "1",
doi = "10.1254/jjp.61.157",
language = "English",
volume = "61",
pages = "157--163",
journal = "Japanese Journal of Pharmacology",
issn = "0021-5198",
publisher = "Japanese Pharmacological Society",
number = "3",

}

Amano, M, Hasegawa, T, Nabeshima, T, Amano, M, Goto, A & Takahash, N 1993, 'Effects of BMY-21502 on Anoxia in Mice', The Japanese Journal of Pharmacology, vol. 61, no. 3, pp. 157-163. https://doi.org/10.1254/jjp.61.157

Effects of BMY-21502 on Anoxia in Mice. / Amano, Manabu; Hasegawa, Takaaki; Nabeshima, Toshitaka; Amano, Manabu; Goto, Arata; Takahash, Norimitsu.

In: The Japanese Journal of Pharmacology, Vol. 61, No. 3, 01.01.1993, p. 157-163.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of BMY-21502 on Anoxia in Mice

AU - Amano, Manabu

AU - Hasegawa, Takaaki

AU - Nabeshima, Toshitaka

AU - Amano, Manabu

AU - Goto, Arata

AU - Takahash, Norimitsu

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The protective effects of BMY-21502 (l-[[l-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone) against cerebral anoxia were investigated using various models in mice, in comparison with those of other cerebroactive drugs. Oral administration of BMY-21502 (10-100 mg/kg) significantly prolonged the survival time in KCN (2.4 mg/kg, i.v.)-induced anoxia. Oxiracetam and idebenone exerted similar but weak protection at doses above 100 mg/kg, p.o. and only at a dose of 1(X) mg/kg, P.O., respectively. Significant protection by BMY-21502 against moderate hypobaric hypoxia was observed at doses of 30 and 100 mg/kg, p.o. Idebenone (100 and 300 mg/kg, p.o.) significantly prolonged the survival time of mice in this model, but oxiracetam (30-300 mg/kg, p.o.) did not. Oral administration of all of these drugs (BMY-21502, 3-300 mg/kg; Oxiracetam, 100-1000 mg/kg; Idebenone, 100-1000 mg/kg) failed to increase the number of gasps and the duration of gasping in the decapitated head of mice as a complete ischemic model. The anti-anoxic effect of BMY-21502 in the KCN-anoxia model was blocked by pretreatment with scopolamine. These findings suggest that BMY-21502 has an anti-anoxic action superior to those of the other cerebroactive drugs used, and activation of the CNS cholinergic system is involved as one of the causative mechanisms for the anti-anoxic effect of BMY-21502.

AB - The protective effects of BMY-21502 (l-[[l-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone) against cerebral anoxia were investigated using various models in mice, in comparison with those of other cerebroactive drugs. Oral administration of BMY-21502 (10-100 mg/kg) significantly prolonged the survival time in KCN (2.4 mg/kg, i.v.)-induced anoxia. Oxiracetam and idebenone exerted similar but weak protection at doses above 100 mg/kg, p.o. and only at a dose of 1(X) mg/kg, P.O., respectively. Significant protection by BMY-21502 against moderate hypobaric hypoxia was observed at doses of 30 and 100 mg/kg, p.o. Idebenone (100 and 300 mg/kg, p.o.) significantly prolonged the survival time of mice in this model, but oxiracetam (30-300 mg/kg, p.o.) did not. Oral administration of all of these drugs (BMY-21502, 3-300 mg/kg; Oxiracetam, 100-1000 mg/kg; Idebenone, 100-1000 mg/kg) failed to increase the number of gasps and the duration of gasping in the decapitated head of mice as a complete ischemic model. The anti-anoxic effect of BMY-21502 in the KCN-anoxia model was blocked by pretreatment with scopolamine. These findings suggest that BMY-21502 has an anti-anoxic action superior to those of the other cerebroactive drugs used, and activation of the CNS cholinergic system is involved as one of the causative mechanisms for the anti-anoxic effect of BMY-21502.

UR - http://www.scopus.com/inward/record.url?scp=0027192836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027192836&partnerID=8YFLogxK

U2 - 10.1254/jjp.61.157

DO - 10.1254/jjp.61.157

M3 - Article

C2 - 8483292

AN - SCOPUS:0027192836

VL - 61

SP - 157

EP - 163

JO - Japanese Journal of Pharmacology

JF - Japanese Journal of Pharmacology

SN - 0021-5198

IS - 3

ER -